*To the Editor*:

We read with interest the elegant modeling data of Foy and colleagues ([@bib1]), who reported a 40% narrowing of small airways was associated with clinically relevant alterations in asthma control and quality of life. Such effects were commensurate with observed responses to biologics on the frequency-dependent heterogeneity of the resistance component of respiratory impedance measured by impulse oscillometry (IOS), where the mean pooled effect on resistance at 5 Hz (R5) − resistance at 20 Hz (R20) was −0.04 (95% confidence interval \[CI\], −0.03 to −0.05) (kPa/L) ⋅ s.

To further put these changes into clinical context, we previously measured IOS in response to propranolol-induced bronchoconstriction in patients with asthma where there was a 0.05 (kPa/L) ⋅ s increase in R5 − R20 corresponding to a 104.1% (95% CI, 22.6 to 185.6%) change, along with a subsequent bronchodilator response to salbutamol of −0.17 (kPa/L) ⋅ s and −115.6% (95% CI, −55.6% to −175.7%), respectively ([@bib2]). Moreover, in a health informatics evaluation of 302 patients with asthma, there was a 45% increased risk for worse control in relation to oral corticosteroid use, and 47% in relation to inhaled albuterol use measured during a 2-year period when comparing cohorts of patients with asthma, using a cutoff value for R5 − R20 of less than or greater than 0.07 (kPa/L) ⋅ s ([@bib3]).

Hence, the small airway asthma phenotype reflected by abnormal R5 − R20 is associated with poorer control. We believe the findings of Foy and colleagues ([@bib1]) are important in further validating the use of IOS in determining effects of treatments on small airways of patients with asthma.
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